Danaher Co. (NYSE:DHR) Stock Holdings Lessened by Arthur M. Cohen & Associates LLC

Arthur M. Cohen & Associates LLC lowered its position in shares of Danaher Co. (NYSE:DHR) by 0.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 212,639 shares of the conglomerate’s stock after selling 1,623 shares during the period. Danaher accounts for about 8.7% of Arthur M. Cohen & Associates LLC’s holdings, making the stock its 2nd biggest position. Arthur M. Cohen & Associates LLC’s holdings in Danaher were worth $48,811,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of DHR. Benjamin Edwards Inc. lifted its position in shares of Danaher by 1.8% in the second quarter. Benjamin Edwards Inc. now owns 2,153 shares of the conglomerate’s stock worth $538,000 after buying an additional 38 shares in the last quarter. Wedge Capital Management L L P NC raised its holdings in shares of Danaher by 3.2% during the 3rd quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock worth $342,000 after acquiring an additional 38 shares in the last quarter. Certified Advisory Corp boosted its position in shares of Danaher by 4.5% during the 2nd quarter. Certified Advisory Corp now owns 926 shares of the conglomerate’s stock valued at $231,000 after acquiring an additional 40 shares during the last quarter. Meridian Financial Partners LLC grew its holdings in shares of Danaher by 4.4% in the third quarter. Meridian Financial Partners LLC now owns 957 shares of the conglomerate’s stock valued at $266,000 after purchasing an additional 40 shares in the last quarter. Finally, Kovack Advisors Inc. increased its position in Danaher by 3.4% in the third quarter. Kovack Advisors Inc. now owns 1,243 shares of the conglomerate’s stock worth $346,000 after purchasing an additional 41 shares during the last quarter. Institutional investors own 79.05% of the company’s stock.

Danaher Trading Down 1.4 %

Shares of NYSE:DHR opened at $238.41 on Friday. The company has a market capitalization of $172.20 billion, a PE ratio of 45.50, a P/E/G ratio of 4.23 and a beta of 0.83. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. Danaher Co. has a 12-month low of $222.53 and a 12-month high of $281.70. The business’s fifty day simple moving average is $234.99 and its 200-day simple moving average is $253.37.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.57 by $0.14. The company had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The firm’s quarterly revenue was up 3.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.02 earnings per share. As a group, equities research analysts predict that Danaher Co. will post 7.49 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be given a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.45%. Danaher’s payout ratio is 20.61%.

Wall Street Analyst Weigh In

Several equities analysts have commented on DHR shares. StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a research report on Saturday, December 14th. KeyCorp lifted their price target on Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 23rd. Wolfe Research upgraded Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective on the stock in a research report on Thursday, October 31st. Raymond James lowered their price objective on Danaher from $310.00 to $300.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. Finally, Robert W. Baird cut their target price on Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. Six research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $286.80.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.